Every provider on this page has been verified.

MSCP (Menopause Society Certified Practitioner) is a competency credential issued by The Menopause Society (formerly NAMS). Clinicians must pass a proctored exam covering menopause physiology, hormone therapy, and management of vasomotor and genitourinary symptoms, and recertify every three years. As of 2024 there are roughly 1,500 active MSCP holders in the United States. Source: The Menopause Society, menopause.org/professional-education/mscp-program.

Every published provider holds a valid NPI (CMS NPPES, https://npiregistry.cms.hhs.gov), a current state medical license that is not disciplined, and at least one menopause-care credential — MSCP, legacy NAMS, or ABMS board certification in OB/GYN, Internal Medicine, Endocrinology, or Family Medicine (https://www.certificationmatters.org). Their clinic website must explicitly offer menopause or HRT services. The credential set was chosen to match the qualifications endorsed in the Menopause Society 2022 Hormone Therapy Position Statement.

For most healthy women under age 60 or within 10 years of menopause onset, the benefits of systemic hormone therapy for treating vasomotor symptoms and preventing bone loss outweigh the risks. This is the explicit conclusion of the 2022 Hormone Therapy Position Statement of The Menopause Society, published in Menopause 29(7):767–794, doi:10.1097/GME.0000000000002028. The same position is held by ACOG (Practice Bulletin No. 141, reaffirmed 2023) and the Endocrine Society 2015 Clinical Practice Guideline on menopausal hormone therapy.

FDA-approved bioidentical hormones (estradiol patches, oral micronized progesterone such as Prometrium) are mass-manufactured to defined potency and purity. Compounded bioidentical hormones are mixed by a compounding pharmacy from a clinician prescription and are not FDA-approved for safety, efficacy, or batch consistency. The 2020 National Academies of Sciences consensus report The Clinical Utility of Compounded Bioidentical Hormone Therapy concluded the evidence does not support routine use of compounded preparations and recommended FDA-approved products as first line.

There is no FDA-approved testosterone product for women in the United States as of 2026. Off-label transdermal testosterone in physiologic female doses is supported for postmenopausal hypoactive sexual desire disorder (HSDD) by the 2019 Global Consensus Position Statement on the Use of Testosterone Therapy for Women, co-endorsed by The Menopause Society, the Endocrine Society, and the International Menopause Society, published in The Journal of Clinical Endocrinology & Metabolism 104(10):4660–4666. The consensus statement explicitly recommends against pellet implants and against testosterone use for indications other than HSDD.

No. Providers cannot buy a listing. Inclusion is determined solely by credential verification against primary sources (CMS NPPES, state medical boards, ABMS). Monetization is limited to telehealth affiliate links clearly marked rel=sponsored, which do not influence provider placement.

Every provider page displays a "Verified" timestamp showing the date of the last credential check. NPI status, state license status, and board certification are re-verified against CMS NPPES, state medical board APIs, and ABMS on a rolling 90-day cadence.

Yes. Menopause telehealth services (Midi Health, Alloy, Evernow, Winona, Hers Menopause) now cover all 50 US states. Each state page lists the telehealth services covering that state, and every provider page includes a state-matched telehealth option. See /telehealth/best-menopause-telehealth/ for our ranked comparison.